CivaTech Oncology Inc. has developed a new U.S. Food and Drug Administration (FDA)-cleared radiation source. The CivaString source features 103Pd (palladium) along the full length of the device, which is contained using low-Z polymers.

A spinout from Oxford’s Department of Engineering Science has raised £1 million from a high net worth Chinese investor to develop an imaging technology which could help doctors detect cancers, particularly prostate and liver tumors. Early diagnosis of cancer has been shown to save lives, and the Oxford technology will allow for improved visualization of tumors for earlier detection.

To provide the best possible patient experience with superb image quality, Indiana University Health Goshen Hospital installed the Vantage Titan 1.5T magnetic resonance (MR) system from Toshiba America Medical Systems Inc. Goshen is a part of Indiana’s largest integrated delivery network (IDN) and is utilizing the system in the hospital to support its heart and vascular center to improve patient outcomes with high-quality imaging and a comprehensive suite of patient-focused technologies.

Mirada Medical Ltd, a medical imaging software company, and BTG plc, a global specialist healthcare company, announced a collaboration to develop dosimetry software solutions to optimize radioembolization therapy with TheraSphere.

Mevion Medical Systems announced that Ackerman Cancer Center (ACC) in Jacksonville, Florida, will install a second Mevion S250 Series proton therapy system. ACC began treating cancer patients with its first S250 system in April, and is already treating enough patients to warrant the installation of a second system. ACC achieved the fastest per-room ramp-up in the history of proton therapy, reaching an annualized rate of 350 patients per year, more than 25 percent better than the average U.S. proton therapy center.